Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000649099 | SCV000770924 | likely benign | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2023-10-14 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003144436 | SCV003831395 | uncertain significance | not provided | 2019-06-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003303060 | SCV003998840 | uncertain significance | Cardiovascular phenotype | 2023-04-18 | criteria provided, single submitter | clinical testing | The p.V769L variant (also known as c.2305G>T), located in coding exon 15 of the FLNC gene, results from a G to T substitution at nucleotide position 2305. The valine at codon 769 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |